Long known for their role in histone acetylation, recent studies have demonstrated that lysine acetyltransferases also carry out distinct "orphan" functions. These activities impact a wide range of biological phenomena including metabolism, RNA modification, nuclear morphology, and mitochondrial function. Here, we review the discovery and characterization of orphan lysine acetyltransferase functions. In addition to highlighting the evidence and biological role for these functions in human disease, we discuss the part emerging chemical tools may play in investigating this versatile enzyme superfamily.
Long known for their role in histone acetylation, recent studies have demonstrated that lysine acetyltransferases also carry out distinct "orphan" functions. These activities impact a wide range of biological phenomena including metabolism, RNA modification, nuclear morphology, and mitochondrial function. Here, we review the discovery and characterization of orphan lysineacetyltransferase functions. In addition to highlighting the evidence and biological role for these functions in human disease, we discuss the part emerging chemical tools may play in investigating this versatile enzyme superfamily.
Acetylation
is a macromolecular
modification well-known for its role in histone modification and regulation
of genomic function (Figure 1). The first enzyme
catalyzing this process, the lysineacetyltransferase (KAT) Gcn5,
was identified in 1995 from the protozoan Tetrahymena on the basis
of its ability to transfer radiolabeled acetyl-CoA to a histone impregnated
gel slice.[1] In the 20 years since this
discovery, our understanding of the role of acetylation in biology
has evolved rapidly.[2] The biomedical impact
of this revolution has been similarly rapid and remarkable.[3] KAT function is antagonized by lysine deacetylase
(KDAC) enzymes, and inhibitors of this process have been clinically
approved for the treatment of T-cell lymphoma.[4,5] More
recently, inhibitors of bromodomains—structural motifs that
interact with the KAT-catalyzed acetyl-lysine modification—have
also shown antitumor efficacy in preclinical studies.[6,7]
Figure 1
Regulation
of protein activity by acetylation. Lysine acetyltransferase
(KAT) enzymes catalyze nucleophilic attack of the electrophilic acetyl-CoA
thioester by the ε-amine of protein lysine residues. This modification
is recognized by bromodomains and removed by lysine deacetylase (KDAC)
enzymes (not shown). Through these modificatons, lysine acetyltransferases
can modulate diverse cellular phenomena including chromatin structure,
enzyme activity, and protein stability.
Regulation
of protein activity by acetylation. Lysineacetyltransferase
(KAT) enzymes catalyze nucleophilic attack of the electrophilic acetyl-CoA
thioester by the ε-amine of protein lysine residues. This modification
is recognized by bromodomains and removed by lysine deacetylase (KDAC)
enzymes (not shown). Through these modificatons, lysine acetyltransferases
can modulate diverse cellular phenomena including chromatin structure,
enzyme activity, and protein stability.The finding that therapeutic benefits can be derived from
both
targeting the proteins that remove acetylation (KDACs) and those that
recognize it (bromodomains) exemplifies the complexity of acetylation
biology. This complexity was compounded in 2009, when the advent of
new immunoprecipitation methods and improved analytical tools led
to the discovery that a large portion of the human proteome (now estimated
at over 4000 sites) are subject to lysine acetylation (Figure 1).[8,9] One implication of these findings
is that the cellular acetyltransferase program may be more diverse
than previously recognized. However, while tremendous advances have
been made in our understanding of cellular KAT function, these studies
have focused heavily on a few main enzyme families: Gcn5/pCAF, p300/CBP,
and MYST. These “canonical” KATs have been the subject
of extensive characterization due to their essential roles in transcription,
replication, and DNA repair, work summarized in several excellent
articles.[10−14] In this review, our goal is to complement knowledge gained in the
study of these core KAT families by shifting our focus to less well-known
and emerging paradigms in KAT biology, specifically what we term “orphan”
KAT functions. Many of these functions do not involve modification
of histones, are not carried out in the nucleus, and mediate biological
functions distinct from transcription. Specifically, we focus on (1)
p300, a canonical KAT with the ability to install non-nuclear acetyl-
and acyl-lysine modifications; (2) Elp3, a KAT involved in RNA modification;
(3) Nat10 and (4) Gcn5L1, two recently characterized KATs that play
roles in tubulin and mitochondrial acetylation, respectively; and
(5) Acat1, a primary metabolic enzyme that recent evidence suggests
moonlights as a mitochondrial KAT. By focusing on orphan KAT function
through the prism of these five enzymes, we seek to emphasize findings
that add to previously established concepts and highlight new directions
of inquiry. Finally, we conclude with a summary of open questions
and potential paths forward for the field.
A Well-Known KAT Responsible
for Orphan Modifications: p300
The transcriptional coactivator p300 is a large (300 kDa)
acetyltransferase
enzyme found in all metazoans.[10] The p300KAT domain shares 87% amino acid identity with another acetyltransferase,
CBP, although the two proteins are functionally distinct. Despite
being one of the first discovered and most well-characterized KAT
enzymes,[15] recent literature suggests p300
also possesses some less well-understood and emerging functions. These
derive from its ability to utilize a diverse range of substrates and
acyl-CoA cofactors, which we term p300’s “orphan”
activities.Focusing on acetylation, p300 has been shown to
catalyze acetylation
of nonhistone targets such as transcription factors, metabolic enzymes,
kinases, other KATs, cytoskeletal components, and a multitude of other
proteins (Figure 1). This is facilitated biochemically
by p300’s utilization of a relatively uncommon Theorell-Chance
mechanism, in which the protein lysine substrate is proposed to bind
rapidly to the preformed p300/acetyl-CoA complex, and undergo acyl
transfer without formation of a stable ternary complex.[16,17] One example illustrating this radical substrate tolerance came during
recombinant expression of the p300 domain in E. coli. In this study, Cole and co-workers found that p300 expression was
greatly improved by coexpression of the yeast KDAC Sir2. The implication
of this finding was that overexpressed humanp300 has sufficient promiscuity
to acetylate bacterial protein targets, and that it does so to a degree
that promotes toxicity.[18] These findings
suggest caution may be warranted when attributing the acetylation
of specific substrates to the activity of p300 (or other canonical
KATs) based on overexpression experiments alone.In addition
to diverse substrates, an emerging body of literature
indicates that lysine residues are modified by diverse acyl-modifications,
including propionyl-, butyryl-, malonyl-, succinyl-, crotonyl-, hydroxybutyrl-,
3-phosphoglyceryl-, palmitoyl-, and myristoyl (Figure 2a).[19−23] Indeed, while by no means a fait accompli, at this
point it may be reasonable to speculate that most metabolic acyl-CoAs
are capable of modifying lysine residues and that additional modifications
will be discovered as analytic tools become more powerful (Figure 2b). A major challenge lies in understanding how
and/or whether these marks are regulated. Notably, some KDACs have
been found to remove alternative acyl-CoA modifications with vastly
different rates (reviewed in this journal).[24] While the KATs governing this process are less well-understood,
an early study demonstrated that p300 is able to utilize propionyl-
and butyryl-CoA as histone acylation cofactors in vitro.[23] This property is shared by CBP, Gcn5,
and pCAF.[25,26] The transfer of these longer acyl-chains
occurs more slowly than acetylation.[25] Hang
and co-workers exploited this property to identify direct p300 substrates
by utilizing pentynoyl-CoA, an extended acyl-CoA bearing a latent
affinity handle whose transfer to lysine substrates could be enriched
and detected by LC-MS/MS.[27] In addition
to propionylation (C3), butyrylation (C4), and pentynoylation (C5),
a recent publication reported p300 is capable of transferring succinyl-
(C4) and glutaryl-CoA (C5) acyl units to a histone H4 peptide substrate
(Figure 2).[28] While
this phenomenon will require kinetic characterization in order to
understand its physiological relevance, it suggests p300 can also
accommodate negatively charged acyl-CoA cofactors in a conformation
that is compatible with the binding of protein substrates.
Figure 2
Lysine acylations
derived from nonacetyl, metabolic acyl-CoA cofactors.
(a) Lysine acylations that have been identified or analyzed in functional
studies to date. Notably, each family of modification imbues the lysine
side-chain with a unique physiochemical property. (b) Examples of
lysine acylations that have not been identified but that may be hypothesized
to exist based on the abundance of their cellular acyl-CoAs. Notably,
each of these speculative modifications would imbue the lysine side-chain
with novel physiochemical properties.
Lysine acylations
derived from nonacetyl, metabolic acyl-CoA cofactors.
(a) Lysine acylations that have been identified or analyzed in functional
studies to date. Notably, each family of modification imbues the lysine
side-chain with a unique physiochemical property. (b) Examples of
lysine acylations that have not been identified but that may be hypothesized
to exist based on the abundance of their cellular acyl-CoAs. Notably,
each of these speculative modifications would imbue the lysine side-chain
with novel physiochemical properties.While such studies are in their early stages, an emerging
hypothesis
is that the cofactor promiscuity exhibited by p300 (and other KATs)
may allow them to act as metabolic sensors, relaying signals about
cellular acyl-CoA levels to histone or nonhistone proteins to mediate
their activity.[29,30] Such a role would be consistent
with recent studies demonstrating p300 acts as a metabolic sensor
in suppressing autophagy under conditions in which nucleocytosolic
acetyl-CoA levels are elevated.[31] Interestingly,
biochemical characterization of p300 indicates the enzyme possesses
a Km for acetyl-CoA far below measured
cellular acyl-CoA concentrations. This suggests p300 may be sensitive
to subcellular fluctuations in local, rather than global, acetyl-CoA
levels. Determining how KAT catalytic activity is affected by the
availability and subcellular biosynthesis of alternative acyl-CoA
cofactors will be an important step toward defining their functional
connection to metabolism in vivo.
Jack of All
Trades (Protein, RNA, DNA?): Elp3
Elp3 was first identified as the catalytic KAT subunit
of Elongator,
a multiprotein complex that copurifies with transcriptionally engaged
RNA Polymerase II (RNAPII) in yeast.[32] Subsequent
studies demonstrated Elp3 is biochemically competent as a KAT, can
facilitate acetyl-CoA-dependent RNAPII transcription through chromatin,
and is required for a subset of H3 acetylation events in cells.[33−35] In addition to histones, Elp3 and its species-specific homologues
have also been demonstrated to acetylate other proteins including
tubulin,[36] the Drosophila neuronal protein Bruchpilot,[37] and the
pentose phosphate enzyme glucose-6-phosphate dehydrogenase.[38]While these findings mark Elp3 as a versatile
and biologically
relevant KAT, this enzyme’s “orphan” designation
arises from its ability to facilitate acetyl-CoA-based modification
of a remarkably different class of macromolecule: RNA. Several acetyl-CoA-based
modifications of RNA have been identified (Figure 3a). These include 5-carboxymethylation of uridine, found in
the modified nucleosides cm5U, mcm5U, mcm5s2U, and ncm5U (generally referred to
here as xm5U).[39] These modifications
are implemented post-transcriptionally and can be found in over 25%
of yeast tRNAs, where they help regulate mRNA decoding and translational
fidelity. Elp3’s involvement in RNA modification was identified
through the study of a fission yeast mutant demonstrating defective
suppressor tRNA function.[40] Genetic analyses
mapped the mutation to the Elp3 locus, and it was found that an active
Elp3KAT domain was required for incorporation of xm5U
modifications into yeast tRNA. This finding helped explain the molecular
basis for the observation that genetic ablation of Elp3 confers resistance
to the killer yeast toxin zymocin, an xm5U-specific RNase.[41] Furthermore, Bystrom and co-workers determined
that many of the phenotypes associated with Elp3 loss in budding yeast,
including temperature-sensitive growth, could be suppressed by overexpression
of two tRNA genes.[42] Interestingly, overexpression
of these two tRNAs also restores histone acetylation defects observed
in Elp3-deficient yeast. This potentially indicates that RNA regulation
is Elp3’s primary function and that downstream effects (such
as loss of specific histone acetylation events) represent indirect
epi-phenomena.
Figure 3
Acetyl-CoA dependent modifications of RNA. (a) Examples
of acetyl-CoA
derived modifications that have been identified in prokaryotic and
eukaryotic organisms. The acetyl-CoA derived portion of each RNA modification
is pictured in blue. (b) Mechanism of Elp3-catalyzed tRNA modification.
Binding of S-adenosine methionine (SAM) and tRNA catalyzes formation
of an adenosyl-radical by the Elp3 Fe–S cluster, which, in
turn, abstracts a hydrogen from acetyl-CoA. The acetyl-CoA radical
undergoes C–C bond formation with adenosine, followed by electron
loss, and general base catalysis to form the acetyl-CoA-RNA adduct.
Subsequent hydrolysis yields the carboxymethylated tRNA product.
Acetyl-CoA dependent modifications of RNA. (a) Examples
of acetyl-CoA
derived modifications that have been identified in prokaryotic and
eukaryotic organisms. The acetyl-CoA derived portion of each RNA modification
is pictured in blue. (b) Mechanism of Elp3-catalyzed tRNA modification.
Binding of S-adenosine methionine (SAM) and tRNA catalyzes formation
of an adenosyl-radical by the Elp3Fe–S cluster, which, in
turn, abstracts a hydrogen from acetyl-CoA. The acetyl-CoA radical
undergoes C–C bond formation with adenosine, followed by electron
loss, and general base catalysis to form the acetyl-CoA-RNA adduct.
Subsequent hydrolysis yields the carboxymethylated tRNA product.While these studies provided strong
evidence for the involvement
of Elp3 in RNA modification, the mechanistic basis for this activity
was only recently described. Elp3 is unique among known multidomain
acetyltransferases in that it houses an iron–sulfur (Fe–S)
cluster, frequently associated with radical SAM enzymes. Evidence
for the participation of this domain in RNA carboxymethylation was
provided by its high conservation, as well as studies showing Fe–S
cluster biosynthesis is essential for xm5U synthesis.[43] This led Huang and co-workers to determine an
elegant, radical SAM-based mechanism for Elp3-catalyzed uridine carboxymethylation.[44] Isotopic labeling experiments using an archael
Elp3 supported a mechanism in which tRNA carboxymethylation proceeds
via an initial SAM radical-mediated abstraction of the acetyl-CoA
C2-hydrogen, followed by C–C bond formation with uridine C5-hydrogen.
Subsequent hydrolysis of the uridine-acetyl-thioester intermediate
yields the final 5-carboxymethyluridine product (Figure 3b). The authors also observed that Elp3 alone hydrolyzed acetyl-CoA,
potentially indicative of a covalent acetyl-enzyme intermediate. Notably,
analogous acetyl-enzyme intermediates have been proposed to be critical
in lysineacetyltransferase reactions.[45]Elp3 represents a fascinating example of an orphan KAT with
multiple
distinct biological functions. However, a number of questions remain.
For example, Huang and co-workers note that Elp3, but not other members
of the Elongator complex, is highly conserved among many lower organisms
and viruses.[44] This suggests Elp3’s
RNA carboxymethylation function may have arisen relatively early in
evolution, before later being co-opted for protein lysine acetylation.
As noted above, in yeast, tRNA-dependent effects of Elp3 appear to
lie upstream of at least some histone acetylation events. However,
in human cells, Elongator can be found associated with the coding
regions of many genes.[35] These contrasting
observations raise the question of whether Elp3 functions primarily
as a KAT or an RNA carboxymethyltransferase in higher organisms. An
important step toward unraveling this dichotomy will be to map the
molecular targets of the xm5U modifications in eukaryotic
RNAs. In this respect, it is remarkable that pseudouridinylation,
another primarily tRNA associated post-transcriptional modification,
was recently found in diverse messenger and noncoding RNAs when interrogated
by next-generation sequencing.[46,47]In addition to
Elp3, homologues of Nat10—another eukaryotic
protein acetyltransferase—have been demonstrated to catalyze
post-transcriptional acetylation of tRNA and rRNA cytidine residues.[48] One broad implication of these studies is that
protein and nucleic acid modifications may be functionally linked
to a greater degree than is currently known. For example, Fe(II)-ketoglutarate-dependent
dioxygenase family members catalyze removal of methyl groups from
protein, RNA, and DNA.[49−51] However, to our knowledge, the ability of any single
dioxygenase to catalyze both protein and DNA oxidation has not been
reported. Interestingly, in addition to its role in protein and RNA
modification, Elp3 knockdown has also been reported to facilitate
epigenetic reprogramming of paternal DNA demethylation in mice.[52] Mutational analyses indicate this function requires
the active radical SAM domain, while the HAT domain is dispensable.
Understanding the molecular basis for the integration of these multiple
activities will be an important area of future research.
A Cytoskeletal
Orphan Acetyltransferase: Nat10
Another acetyltransferase that appears to exhibit multiple,
context-dependent
functions is the nucleolar acetyltransferaseNat10. HumanNat10 (not
to be confused with the N-terminal acetyltransferase Naa10) was first
identified as a histone acetyltransferase facilitating transcriptional
coactivation of the telomerase gene.[53] Functional
studies demonstrated a truncated Nat10 construct was able to catalyze
transfer of 14C-acetyl-CoA to histones in vitro. Specific sites of acetylation were investigated in a subsequent
study that demonstrated a role for Nat10 in reformation of the nuclear
envelope following mitosis.[54] Knockdown
of Sun1, a factor involved in Nat10-chromosomal targeting, primarily
reduced acetylation of histones H2B (K12 and K15) and H4 (K8, K12,
K16). Nat10 acetylation of these sites was proposed to facilitate
chromatin decondensation following cell division, priming chromatin
for gene expression during interphase.[54]In addition to histone acetylation, evidence suggests Nat10
also
harbors tubulinacetyltransferase activity (Figure 4). Tubulinlysine acetylation is a highly conserved post-translational
modification associated with stable, long-lived microtubules and has
been shown to play a role in cell migration and neuronal function
in higher organisms.[55] Following up on
the involvement of Nat10 in mitosis, Zhang and co-workers found Nat10
exhibited cell-cycle dependent localization to the midbody, a tubulin-rich
structure transiently formed near the end of cytokinesis just prior
to cell division.[56] Depletion of Nat10
also blunted the induction of tubulin acetylation and impaired cytokinesis.
While biochemical acetyltransferase activity was not demonstrated,
these data suggest Nat10 may directly mediate tubulin acetylation.
This finding is intriguing for a number of reasons. First, other studies
have identified an alternative acetyltransferase, αTAT1, as
the major tubulinacetyltransferase in higher organisms.[57,58] The degree to which these activities are redundant or context-dependent
remains to be established. Second, since tubulin acetylation facilitates
tubulin stability and reduced cellular motility, restoration of tubulin
acetylation using HDAC inhibitors has been actively explored as an
approach to limit cancer cell metastasis.[59] However, Nat10 is upregulated in a number of cancers and is nonintuitively
associated with increased cellular motility and invasion in colorectal
cancer.[56,60] This correlates with the recent finding
that inhibition of αTAT1 can reduce tumor cell migration,[61] and suggests the dynamics, rather than overall
balance, of tubulin acetylation may be most important for proliferation
and invasion.
Figure 4
Role of the orphan acetyltransferase Nat10 in regulation
of nuclear
shape in laminopathic disorders. Left: Nat10-catalyzed acetylation
contributes to external forces exerted on the nuclear membrane. Middle:
In HGPS cells, an altered form of nuclear lamin (progerin) accumulates,
resulting in abnormal susceptibility to external forces and defects
in nuclear shape (known as blebbing). Right: Inhibition of Nat10 by
a small molecule (remodelin) reduces acetylation-dependent external
nuclear forces, thereby restoring normal nuclear shape.
Role of the orphan acetyltransferaseNat10 in regulation
of nuclear
shape in laminopathic disorders. Left: Nat10-catalyzed acetylation
contributes to external forces exerted on the nuclear membrane. Middle:
In HGPS cells, an altered form of nuclear lamin (progerin) accumulates,
resulting in abnormal susceptibility to external forces and defects
in nuclear shape (known as blebbing). Right: Inhibition of Nat10 by
a small molecule (remodelin) reduces acetylation-dependent external
nuclear forces, thereby restoring normal nuclear shape.Along with cancer, therapeutic targeting of Nat10
has recently
been proposed for treatment of Hutchinson–Gilford progeria
syndrome (HGPS), a premature-aging disease.[62] HGPS and related disorders result from mutation of the gene LMNA, which encodes the nuclear membrane proteins lamin
A and C.[63] These mutations cause production
of progerin, a truncated lamin A precursor. Unlike lamin A, progerin
remains anchored to the nuclear membrane, causing the nucleus to be
abnormally susceptible to external forces. This manifests as a number
of overt phenotypes, including misshapen nuclei and loss of repressive
chromatin domains. The latter characteristic led Jackson and co-workers
to examine a small panel of nine previously characterized KAT and
HDAC inhibitors in a cell-based model of lamin deficiency to determine
their effect on nuclear morphology.[62] Only
one molecule demonstrated significant rescue of the laminopathic nuclear
shape defect, a small molecule previously identified as an inhibitor
of the acetyltransferaseGcn5.[64] Chemical
derivatization of the small molecule with a biotin affinity handle
and subsequent pulldown from cell lysates identified a number of prospective
molecular targets, including lamin C, several RNA-binding proteins,
and the acetyltransferaseNat10. This prompted a series of follow-up
experiments in which it was rigorously demonstrated that a functional
Nat10acetyltransferase domain is required for maximal induction of
lamin-dependent nuclear shape defects in model systems and HGPSpatient-derived
cells. A derivative of the initial small molecule hit, “remodelin”
(Figure 4), was shown to reduce DNA damage
and cell senescence phenotypes normally observed in HGPS cell lines.[62] Overall, these studies led to the hypothesis
that Nat10-catalyzed acetylation stabilizes microtubule anchorage,
which in turn exerts an external force on the nucleus that contributes
to irregular morphology in cells where progerin has aberrantly accumulated
in nuclear membranes. By reducing these external forces, small molecule
inhibitors of Nat10 can restore normal nuclear shape and thus provide
a new therapeutic avenue for treatment of the symptoms associated
with this phenotype in HGPS.These studies highlight Nat10 as
a biologically relevant orphan
acetyltransferase. Efforts to target Nat10 in cancer and laminopathic
disorders will be facilitated by the biochemical and molecular characterization
of Nat10, including specific sites of tubulin acetylation, which remain
to be determined. It will also be key to further characterize the
protein partners of Nat10, such as the short isoform of the bromodomain
BRD4 with which it interacts in humancancer cells.[65] Similar to Elp3, prokaryotic and eukaryotic homologues
of Nat10 have also been directly implicated in RNA modification, specifically
the posttranscriptional acetylation of cytidine.[48,66] This activity was recently described to regulate the biogenesis
of 18S rRNA in budding yeast.[48] Notably,
humanNat10 contains putative helicase and tRNA-binding domains in
addition to its acetyltransferase domain and has been reported to
play a role in rRNA maturation, suggesting this function may be conserved.[67] Unraveling the hierarchy of these biological
functions will be crucial to determine the targetable role of Nat10
in human disease.
Potential Mitochondrial Acetyltransferase: Gcn5L1
A major finding
arising from unbiased profiling of the cellular
acetylome was the discovery that a high proportion of mitochondrial
enzymes are acetylated (Figure 5).[8] This was unexpected, given that most well-studied
KATs and KAT substrates had been characterized as nucleocytosolic
proteins. Mitochondrial protein acetylation is functional and regulates
the activity of many metabolic enzymes including those involved in
fatty acid oxidation and ketone body production.[68,69] In addition, Sirt3, a mitochondrial deacetylase, can function as
a tumor suppressor.[70] Thus, the question
arises: how are mitochondrial proteins acetylated? Three alternative
hypotheses have emerged: (1) mitochondrial proteins are preacetylated
in the cytoplasm before mitochondrial import, (2) mitochondrial proteins
are nonenzymatically acetylated due to the chemical conditions of
the mitochondrial matrix, or (3) acetylation is driven by uncharacterized
“orphan” mitochondrial acetyltransferases (Figure 5). Notably, these hypotheses are not mutually exclusive.
Figure 5
Mechanisms
of mitochondrial protein acetylation. Hypothetical and
experimental evidence suggests the following three pathways may contribute
to the acetylation of mitochondrial proteins. (1) Proteins may be
acetylated by nucleocytosolic KATs following protein synthesis, prior
to import into the mitochondria (top). (2) Proteins may undergo nonspecific
reaction with acetyl-CoA electrophiles (middle left). (3) Proteins
may be acetylated by specific, mitochondrially localized KAT enzymes
(bottom right).
Mechanisms
of mitochondrial protein acetylation. Hypothetical and
experimental evidence suggests the following three pathways may contribute
to the acetylation of mitochondrial proteins. (1) Proteins may be
acetylated by nucleocytosolic KATs following protein synthesis, prior
to import into the mitochondria (top). (2) Proteins may undergo nonspecific
reaction with acetyl-CoA electrophiles (middle left). (3) Proteins
may be acetylated by specific, mitochondrially localized KAT enzymes
(bottom right).Regarding the first hypothesis,
Hang and co-workers identified
several mitochondrial proteins as putative substrates of p300 using
a bioorthogonal reporter strategy.[27] The
nucleocytosolic localization of p300 would imply these substrates
undergo acetylation prior to mitochondrial import. However, these
studies are far from conclusive, and overall, this potential mechanism
has been largely unexplored. In contrast, prevalent nonenzymatic mitochondrial
protein acetylation has been proposed by several groups. This is supported
by biochemical studies showing nonenzymatic acetylation proceeds rapidly
under conditions similar to those thought to exist in the mitochondrial
matrix (pH 8 and millimolar acetyl-CoA levels).[71] Additionally, proteomic studies have indicated that acetyl-
and succinyl-lysine acylation sites, which derive from the two most
abundant mitochondrial acyl-CoAs, largely overlap, and occur with
low stoichiometry.[72,73] This is consistent with a common,
and potentially nonenzymatic, mechanism. It is important to note that
nonenzymatic acetylation does not necessarily equate with nonfunctional
acetylation. For example, nonenzymatic protein modifications can trigger
important cellular processes capable of amplification (i.e., cell
signaling/gene expression), as observed in signaling mediated by reactive
oxygen species (ROS). Alternatively, nonenzymatic modifications may
be antagonized by highly regulated programs of deacetylation and therefore
have vastly different functional half-lives. A recent review comparing
nonenzymatic acetylation and ROS signaling by Hirschey and co-workers
provided an excellent summary of this perspective.[74]These studies still beg the question: do specific
orphan acetyltransferases
that catalyze mitochondrial protein acetylation exist? To answer this
question, Sack and co-workers applied an innovative bioinformatics
approach to identify factors promoting acetylation of ATPase8, a protein
encoded and produced wholly in the mitochondria.[75] Candidate mitochondrial KATs were identified by searching
a mitochondrial protein database for proteins with homology to Gcn5
(one of the first characterized KAT enzymes). Acetylation of ATPase8
is associated with decreased oxygen consumption; therefore, knockdown
of a mitochondrial KAT would be expected to increase oxygen consumption.
This led to the design of an siRNA screen to assess candidate mitochondrial
KATs for their ability to increase oxygen consumption. Gcn5L1 (also
known as Bloc1s1) emerged as the only candidate protein whose knockdown
promoted this effect. As can be inferred from the gene name, the weak
homology of Gcn5L1 to yeastGcn5 had been noted in an early study.[76] However, the primary biological role attributed
to Gcn5L1 had previously been its involvement in the synthesis of
lysosome-related organelles. Interestingly, while isolated Gcn5L1
exhibited sluggish KAT activity, acetylation was strongly augmented
by the addition of mitochondrial extracts to Gcn5L1. This indicates
Gcn5L1 may only manifest its acetylation activity when other members
of its endogenous protein complex are present. Since these initial
studies, Gcn5L1 has also been reported to be involved in the regulation
of mitophagy.[77,78] However, due to the challenges
of reconstituting its acetyltransferase activity, the biochemical
substrates of Gcn5L1, as well as the degree to which they overlap
with the Sirt3 deacetylation program, remain an open question.Given the limited molecular characterization of Gcn5L1, the question
remains as to whether other mitochondrial KATs may exist (Figure 5). Elp3 has been reported to localize to the mitochondria
in neuronal cells,[79] potentially layering
another level of complexity onto its putative protein, RNA, and DNA
modification functions. In addition, recent studies have provided
evidence that the primary metabolic enzymes Acat and Dlat, both of
which are mitochondrially localized, may also moonlight as protein
acetyltransferases (covered below). Do these enzymes catalyze mitochondrial
protein acetylation, and can enzyme-catalyzed mitochondrial acetylation
events be distinguished from nonenzymatic acetylation by differences
in stoichiometry? Notably, the recent development of two orthogonal
proteomic methods capable of directly interrogating acetylation stoichiometry[80,81] should make answering such questions feasible in the near future.
Metabolic Enzymes Moonlighting as KATs: ACAT1
Related to
the above studies of metabolism and acetylation, very
recent findings have suggested primary metabolic enzymes themselves
harbor intrinsic orphan KAT activities (Figure 5). In studies of the mitochondrial pyruvate dehydrogenase complex,
Chen et al. found that acetylation greatly reduced
the activity of both PDH1, the initial enzyme component of the complex,
as well as PDP1, a phosphatase that functions to stimulate PDH1 activity.[82] This reduction in pyruvate dehydrogenase complex
activity, in turn, limits the conversion of pyruvate to acetyl-CoA
necessary for oxidative phosphorylation by the tricarboxylic acid
cycle (TCA) cycle, thereby facilitating anabolic “Warburg”
metabolism and cancer cell growth in cell and xenograft models.[82] Unexpectedly, an siRNA screen revealed ACAT1
to be the crucial regulator of PDH1/PDP1 acetylation. ACAT1 is a metabolic
thiolase that can catalyze either the biosynthetic condensation of
two acetyl-CoA molecules to acetoacetyl-CoA, or the reverse (degradative)
reaction.[83,84]In vitro studies confirmed
the ability of recombinant ACAT1 to catalyze acetylation of purified
PDH1 and PDP1. Thorough follow-up experimentation demonstrated ACAT1
was essential for pyruvate dehydrogenase-dependent glycolytic metabolism
in a cell-based model of lung cancer. ACAT1 lysineacetyltransferase
activity was also shown to be stimulated by growth factors and blocked
by inhibitors of tyrosine-kinase mediated signaling cascades, indicative
of cross talk between these two regulatory protein modifications.While the scope and specificity of ACAT1-catalyzed protein acetylation
remain to be determined, some evidence suggests the crossover between
metabolic and protein acetylation may be indicative of a more general
phenomenon. For example, the metabolic enzymes ACAT2 and Dlat were
found to stimulate acetylation of cytosolic 6-phosphogluconate dehydrogenase
(6PGDH), a critical regulator of the pentose phosphate pathway.[85] This was initially puzzling, as Dlat itself
is a member of the aforementioned pyruvate dehydrogenase complex,
which exhibits predominantly mitochondrial localization. However,
a landmark study recently observed that in cancer cell lines, growth
factor stimulation can cause nuclear translocation of the pyruvate
dehydrogenase complex, whereupon it is able to directly supply acetyl-CoA
for histone acetylation.[86] Growth factor
signaling was also shown to stimulate Dlat-dependent acetylation of
6PGDH,[85] although further studies will
be necessary to determine whether these two effects are linked. These
studies provide yet another example of the rapid revisions in dogma
that have come to characterize the field of catalytic acetylation
and suggest further investigations into the connection between cancer
metabolism and regulatory protein acetylation events are well-warranted.
Conclusions
and Future Directions
As these examples clearly illustrate,
the field of acetyltransferase
biology is a vibrant and rapidly evolving one. Orphan acetyltransferases
have validated links to cell and disease-associated phenotypes, and
defining their functional roles in signaling represents an essential
step toward targeting these enzymes therapeutically. In our view,
the greatest challenge currently limiting a comprehensive view of
acetyltransferase function stems from the fact that the level of molecular
detail with which each acetyltransferase has been examined varies
widely. This reflects shifts in the availability of experimental techniques,
as well as in attitudes. Akin to the careful enzymological characterization
of canonical KATs performed almost 15 years ago,[15,87] the mechanistic description of Elp3 RNA carboxymethylation illustrates
the ability of biochemical insights to transform our view of novel
biological function on a molecular level.[44] The relative dearth of such studies also provides a call-to-arms
for chemical biologists to craft new tools enabling the rapid, functional
characterization of acetyltransferase activity. To achieve maximal
impact, these tools should be applicable in cellular contexts, as
the discussions of p300, Elp3, and Gcn5L1 exemplify how acetyltransferase
activity can differ greatly between endogenous and artificial settings.
Notably, several recently developed or nascent technologies have demonstrated
utility in such contexts. These include quantitative mass spectrometry
techniques enabling the simultaneous monitoring of multiple histone
acetylation sites,[88] new affinity probes
for examining the active-site occupancy of acetyltransferases in cell
extracts,[26,89] fluorescent reporters that allow live-cell
visualization of protein acetylation,[90,91] and microarray
and chemical genetic methods for identifying putative acetyltransferase
substrates.[92,93] Such methods will benefit from
the continued development of small molecule probes for KAT enzymes[94] and improved Crispr-Cas9 gene editing technologies,
which will facilitate cell-based investigations of KAT activity by
enabling domain specific loss of function studies. The application
of high-throughput techniques for the rapid functional characterization
of KAT activity is the key step necessary to bridge the knowledge
gap that currently lies between canonical KATs such as p300 and Gcn5
and their less-studied orphan relatives. Assembling this knowledge
will allow us to define the role of orphan KATs in acetylation-dependent
signaling cascades, thereby facilitating new efforts to define the
lysine acetylation program and its targetable functions in cancer
and other diseases.
Authors: G Sebastiaan Winkler; Arnold Kristjuhan; Hediye Erdjument-Bromage; Paul Tempst; Jesper Q Svejstrup Journal: Proc Natl Acad Sci U S A Date: 2002-03-19 Impact factor: 11.205
Authors: Stephen J Haggarty; Kathryn M Koeller; Jason C Wong; Christina M Grozinger; Stuart L Schreiber Journal: Proc Natl Acad Sci U S A Date: 2003-04-03 Impact factor: 11.205
Authors: Per Arne Aas; Marit Otterlei; Pål O Falnes; Cathrine B Vågbø; Frank Skorpen; Mansour Akbari; Ottar Sundheim; Magnar Bjørås; Geir Slupphaug; Erling Seeberg; Hans E Krokan Journal: Nature Date: 2003-02-20 Impact factor: 49.962
Authors: J T Davis; R N Moore; B Imperiali; A J Pratt; K Kobayashi; S Masamune; A J Sinskey; C T Walsh; T Fukui; K Tomita Journal: J Biol Chem Date: 1987-01-05 Impact factor: 5.157
Authors: Alexander W Sorum; Jonathan H Shrimp; Allison M Roberts; David C Montgomery; Neil K Tiwari; Madhu Lal-Nag; Anton Simeonov; Ajit Jadhav; Jordan L Meier Journal: ACS Chem Biol Date: 2015-10-14 Impact factor: 5.100
Authors: Rhushikesh A Kulkarni; Andrew J Worth; Thomas T Zengeya; Jonathan H Shrimp; Julie M Garlick; Allison M Roberts; David C Montgomery; Carole Sourbier; Benjamin K Gibbs; Clementina Mesaros; Yien Che Tsai; Sudipto Das; King C Chan; Ming Zhou; Thorkell Andresson; Allan M Weissman; W Marston Linehan; Ian A Blair; Nathaniel W Snyder; Jordan L Meier Journal: Cell Chem Biol Date: 2017-02-02 Impact factor: 8.116
Authors: David C Montgomery; Julie M Garlick; Rhushikesh A Kulkarni; Steven Kennedy; Abdellah Allali-Hassani; Yin-Ming Kuo; Andrew J Andrews; Hong Wu; Masoud Vedadi; Jordan L Meier Journal: J Am Chem Soc Date: 2016-05-17 Impact factor: 15.419
Authors: Wilson R Sinclair; Jonathan H Shrimp; Thomas T Zengeya; Rhushikesh A Kulkarni; Julie M Garlick; Hans Luecke; Andrew J Worth; Ian A Blair; Nathaniel W Snyder; Jordan L Meier Journal: Chem Sci Date: 2017-12-08 Impact factor: 9.825
Authors: Willy V Bienvenut; Annika Brünje; Jean-Baptiste Boyer; Jens S Mühlenbeck; Gautier Bernal; Ines Lassowskat; Cyril Dian; Eric Linster; Trinh V Dinh; Minna M Koskela; Vincent Jung; Julian Seidel; Laura K Schyrba; Aiste Ivanauskaite; Jürgen Eirich; Rüdiger Hell; Dirk Schwarzer; Paula Mulo; Markus Wirtz; Thierry Meinnel; Carmela Giglione; Iris Finkemeier Journal: Mol Syst Biol Date: 2020-07 Impact factor: 11.429
Authors: Jonathan H Shrimp; Yihang Jing; Supuni Thalalla Gamage; Kathryn M Nelson; Joseph Han; Keri M Bryson; David C Montgomery; Justin M Thomas; Kellie D Nance; Sunny Sharma; Stephen D Fox; Thorkell Andressen; Wilson R Sinclair; Hong Wu; Abdellah Allali-Hassani; Guillermo Senisterra; Masoud Vedadi; Denis Lafontaine; Jayme L Dahlin; Ronen Marmorstein; Michael A Walters; Jordan L Meier Journal: ACS Med Chem Lett Date: 2020-07-27 Impact factor: 4.632